179 related articles for article (PubMed ID: 20421219)
21. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
[TBL] [Abstract][Full Text] [Related]
22. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.
Sternberg Z; Hennies C; Sternberg D; Bistulfi GL; Kazim L; Benedict RH; Chadha K; Leung C; Weinstock-Guttman B; Munschauer F
Mult Scler; 2011 Feb; 17(2):157-63. PubMed ID: 20965962
[TBL] [Abstract][Full Text] [Related]
23. Elevated HSP27 levels during attacks in patients with multiple sclerosis.
Ce P; Erkizan O; Gedizlioglu M
Acta Neurol Scand; 2011 Nov; 124(5):317-20. PubMed ID: 21208199
[TBL] [Abstract][Full Text] [Related]
24. Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments.
Foolad F; Samadi-Bahrami Z; Khodagholi F; Nabavi SM; Moore GRW; Javan M
Mol Neurobiol; 2024 Jun; 61(6):3442-3460. PubMed ID: 37995076
[TBL] [Abstract][Full Text] [Related]
25. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
[TBL] [Abstract][Full Text] [Related]
26. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Signoriello E; Lanzillo R; Brescia Morra V; Di Iorio G; Fratta M; Carotenuto A; Lus G
Mult Scler; 2016 Jun; 22(7):921-5. PubMed ID: 26453682
[TBL] [Abstract][Full Text] [Related]
27. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
Ibrahim SH; El-Mehdawy KM; Seleem M; El-Sawalhi MM; Shaheen AA
J Neuroimmunol; 2020 Oct; 347():577356. PubMed ID: 32781341
[TBL] [Abstract][Full Text] [Related]
28. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis.
Hebb AL; Bhan V; Wishart AD; Moore CS; Robertson GS
Curr Drug Discov Technol; 2010 Jun; 7(2):137-40. PubMed ID: 20836755
[TBL] [Abstract][Full Text] [Related]
29. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
[TBL] [Abstract][Full Text] [Related]
30. Plasma biomarkers discriminate clinical forms of multiple sclerosis.
Tejera-Alhambra M; Casrouge A; de Andrés C; Seyfferth A; Ramos-Medina R; Alonso B; Vega J; Fernández-Paredes L; Albert ML; Sánchez-Ramón S
PLoS One; 2015; 10(6):e0128952. PubMed ID: 26039252
[TBL] [Abstract][Full Text] [Related]
31. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
32. Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types.
Greer JM; Trifilieff E; Pender MP
Front Immunol; 2020; 11():1891. PubMed ID: 32973782
[TBL] [Abstract][Full Text] [Related]
33. Multimarker risk stratification approach at multiple sclerosis onset.
Fernández-Paredes L; Casrouge A; Decalf J; de Andrés C; Villar LM; Pérez de Diego R; Alonso B; Álvarez Cermeño JC; Arroyo R; Tejera-Alhambra M; Navarro J; Oreja-Guevara C; López Trascasa M; Seyfferth A; García Martínez MA; Álvarez Lafuente R; Albert ML; Sánchez-Ramón S
Clin Immunol; 2017 Aug; 181():43-50. PubMed ID: 28578025
[TBL] [Abstract][Full Text] [Related]
34. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules.
Durán I; Martínez-Cáceres EM; Río J; Barberà N; Marzo ME; Montalban X
Brain; 1999 Dec; 122 ( Pt 12)():2297-307. PubMed ID: 10581223
[TBL] [Abstract][Full Text] [Related]
35. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Gilbert GJ
Neurology; 2015 May; 84(21):2201. PubMed ID: 26009563
[No Abstract] [Full Text] [Related]
36. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
Thouvenot E; Orsini M; Daures JP; Camu W
Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
[TBL] [Abstract][Full Text] [Related]
37. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
38. Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
Pan G; Simpson S; van der Mei I; Charlesworth JC; Lucas R; Ponsonby AL; Zhou Y; Wu F; Taylor BV
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1204-1211. PubMed ID: 27559181
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
40. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis.
de Jong BA; Westendorp RG; Eskdale J; Uitdehaag BM; Huizinga TW
Hum Immunol; 2002 Apr; 63(4):281-5. PubMed ID: 12039409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
